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oronary Syndrome Setting
estabilizing Another Myth?*
ichael Miller, MD, FACC
altimore, Maryland
or many years, the proclamation that coronary heart disease
CHD) was not attributable to traditional risk factors in up to
0% of cases (1,2) was finally submerged after careful and
etailed re-analysis (3,4). In this issue of the Journal, Pitt
t al. (5) take aim at another long-held notion: that clinically
ignificant alterations in lipids occur after an acute coronary
yndrome (ACS), thereby precluding meaningful interpre-
ation until well beyond hospital discharge.
See page 1440
Modifications of serum lipids after ACS have been
ecognized for at least 50 years (6). They include reductions
n total cholesterol (TC), low-density lipoprotein cholesterol
LDL-C), and high-density lipoprotein cholesterol (HDL-C)
n the range of 10% to 20%, with reciprocal increases in
riglycerides approximating 20% to 30%. These changes were
elieved to commence approximately 24 h after presentation
nd to last up to several months (7–11). Several mechanisms
ccounting for these changes include the acute phase re-
ponse (12,13) associated with up-regulation of low-density
ipoprotein (LDL) receptor activity (14) and reduction in
everal pivotal high-density lipoprotein (HDL) regulatory
roteins (15). In addition, stress-induced myocardial injury
nd necrosis facilitates adrenergic mediated adipocyte lipol-
sis leading to free fatty acid mobilization, enhanced hepatic
ery-low-density lipoprotein (VLDL) secretion, triglyceride
TG) elevation, and alteration in LDL and HDL particle
omposition (16,17). In-hospital therapy and lifestyle changes
re additional contributors to post-ACS lipid changes. For
xample, heparinization results in reduced concentrations of
G and LDL-C owing to lipoprotein lipase (LPL)–mediated
ydrolysis of TG-rich lipoproteins and facilitated uptake of
holesterol by the LDL receptor (18). Conversely, nonselective
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erck–Schering-Plough, and Pfizer.eta-blockers may reduce HDL-C and increase TG by unop-
osed alpha-adrenergic–mediated suppression of hormone-
ensitive lipase (19). Additional contributors to lipid alterations
nclude nonspecific postural effects (20) and reductions in
aturated fat intake that may reduce LDL-C and HDL-C
evels (21). Based on these acute changes, the American
ollege of Cardiology/American Heart Association (ACC/
HA) have supported a Class I recommendation for a fasting
ipid profile analysis to be obtained within 24 h of admission
or ACS (22).
The study by Pitt et al. (5) suggests that lipid levels
emain relatively stable during the initial 96 h after ACS
ased on data from the LUNAR (Limiting UNdertreat-
ent of lipids in ACS with Rosuvastatin) study, a prospec-
ive trial comparing the efficacy of LDL-C lowering with 2
ifferent statins (rosuvastatin and atorvastatin) after hospi-
alization for ACS. As part of the trial, lipid and lipoprotein
evels were assessed on 3 different occasions during the first
hospital days. Although fasting blood samples were not
andated on the admission baseline test, subsequent sam-
les collected on days 2 and 4 were in the fasting state. Five
undred seven patients were evaluated, representing more
han twice the number of participants from the earlier
tudies combined (7–11), and for which direct LDL-C
easurements and fasting TG levels were available. Overall,
he results indicated a similar trend of reduced TC, LDL-C,
nd HDL-C between baseline and the day 2 sample.
owever, these changes were small (2% to 5%) and short-
ived, with rebound increases observed by day 4. From a
linical standpoint, these data provide reassurance that lipid
evels remain relatively stable within the first 96 h after
CS. Unfortunately, what cannot be deduced from the
resent study or its predecessors is the magnitude of LDL-C
eduction compared with the pre-ACS free-living state.
ecause the most profound alterations in lipids and lipopro-
eins are proportional to the extent and severity of myocar-
ial necrosis (9), clinical trials such as LUNAR that gener-
lly exclude complicated patients (e.g., Killip class III/IV,
entricular dysrhythmia) are also likely to underestimate the
otentially greater lipid alterations that may have otherwise
esulted with their inclusion. To this end, it is also not
urprising that older studies, especially those performed in
he pre-thrombolytic and pre-PCI era (6–10), were associ-
ted with bigger lipid effects after ACS compared with more
ecent studies that, in addition to the LUNAR study,
howed smaller changes in post-ACS lipids and/or quicker
eversion to baseline levels (14,23–24).
ow should clinicians apply the results of the present
tudy to their practice? All patients presenting with ACS
eserve lipid and lipoprotein evaluation in the hospital. This
ecision is not predicated on whether to institute in-patient
ipid-lowering therapy, as previously reflected by evidence-
ased data supporting intensive LDL-C reduction post-
CS (25). Rather it serves to reinforce the importance of
nitiating lifestyle and therapeutic measures in-hospital to
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April 15, 2008:1446–7 Editorial Commentaximize secondary prevention efforts that include an
DL-C target of 70 mg/dl (26). The demonstration of
ipid stability extending well into the post-ACS period thereby
engthens the window of opportunity to address these levels
efore hospital discharge and impress on the associated survival
enefits related to adherence of proven therapies (27).
eprint requests and correspondence: Dr. Michael Miller, Uni-
ersity of Maryland Medical Center, Division of Cardiology, Room
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